| March
25, 2007--Beckman
Coulter, Inc. and Biosite Incorporated have announced a
definitive merger agreement.
In the deal, Beckman Coulter acquires all
Biosite’s outstanding common stock in a cash tender
offer of $85.00 per share, making it worth approximately
$1.55 billion on a fully diluted share basis.
The
deal grew out of a collaboration between the two companies
around B-type Natriuretic Peptide (BNP), a test that
supports diagnosis and evaluation of heart failure as well
as risk stratification for heart failure and acute
coronary syndromes.
According
to a company press release, the acquisition “Will
position Beckman Coulter as a leading provider of
immunoassay tests, especially within cardiac
diagnostics.” Beckman
Coulter will leverage its worldwide commercial
infrastructure and installed base to support sales of
Biosite’s tests. The
company also plans to leverage the proteomics firm’s
pipeline of new diagnostics.
For
more information, see the company
press release. |
